Notice of Proposed Sale · 144
Alnylam Pharmaceuticals, Inc.
ALNYNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ALNYLAM PHARMACEUTICALS, INC.
- Issuer CIK
- 0001178670
- SEC file number
- 001-36407
- Phone
- (617) 551-8200
- Person for whose account securities are to be sold
- SUPRAN BRYAN
- Relationships to issuer
- Officer
- Street
- 675 WEST KENDALL STREET
- Street (continued)
- HENRI A. TERMEER SQUARE
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02142
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,758 | 398,862.25 | 133,809,118 | 10/02/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2026 | Restricted Stock Vesting | Issuer | 1,758 | N | 10/01/2026 | Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Notice signature
- Notice date
- 10/02/2026
- Signed
- /s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Bryan A. Supran.
Company context
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio® (inclisiran) and Qfitlia™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.